Related Party Transactions	9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	In November 2018, the Company authorized payment of $3,500 per month to Dr. Hirschman for his services as Chief Executive Officer and $3,500 to Mr. Abrams for his services as a Director. Effective January 1, 2020, Mr. Abrams has waived the payments of fees for his services. Effective April 1, 2020, Dr. Hirschman has waived the payment of is fees as Chief Executive Officer. During the nine months ended September 30, 2020, Dr. Hirschman received aggregate compensation of $3,500 of consulting fees for services as Chief Executive Officer. The Company applied $7,000 of prepaid consulting fees to services for February and March 2020. During the three months ended September 30, 2020, Dr. Hirschman did not receive or accrue new compensation as he has waived his compensation for services as Chief Executive Officer. During the year ended December 31, 2019, Dr. Hirschman received aggregate compensation of $42,000 of consulting fees for services as Chief Executive Officer. During the nine months ended September 30, 2020, Mr. Abrams received payment of accrued consulting fees for services during 2019 in the amount of $14,085. During the three and nine months ended September 30, 2020, Mr. Abrams did not receive or accrue new compensation as he has waived his compensation for services as a Director. During the year ended December 31, 2019, Mr. Abrams received aggregate cash payments of $35,000 for services as a director of the Company. As of September 30, 2020 and December 31, 2019, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $162,409 and $150,968, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes.

Related Party Transactions

9 Months Ended

Sep. 30, 2020

In November 2018, the Company authorized payment of $3,500 per month to Dr. Hirschman for his services as Chief Executive Officer and $3,500 to Mr. Abrams for his services as a Director. Effective January 1, 2020, Mr. Abrams has waived the payments of fees for his services. Effective April 1, 2020, Dr. Hirschman has waived the payment of is fees as Chief Executive Officer.

During the nine months ended September 30, 2020, Dr. Hirschman received aggregate compensation of $3,500 of consulting fees for services as Chief Executive Officer. The Company applied $7,000 of prepaid consulting fees to services for February and March 2020. During the three months ended September 30, 2020, Dr. Hirschman did not receive or accrue new compensation as he has waived his compensation for services as Chief Executive Officer. During the year ended December 31, 2019, Dr. Hirschman received aggregate compensation of $42,000 of consulting fees for services as Chief Executive Officer.

During the nine months ended September 30, 2020, Mr. Abrams received payment of accrued consulting fees for services during 2019 in the amount of $14,085. During the three and nine months ended September 30, 2020, Mr. Abrams did not receive or accrue new compensation as he has waived his compensation for services as a Director. During the year ended December 31, 2019, Mr. Abrams received aggregate cash payments of $35,000 for services as a director of the Company.

As of September 30, 2020 and December 31, 2019, the Company owed Mr. Abrams, a director of the Company, an aggregate total of $162,409 and $150,968, respectively, for outstanding principal and accrued and unpaid interest on certain Bridge Notes.

QUANTRX BIOMEDICAL CORP 10-Q